Aziyo Biologics, which makes regenerative medical products for various tissue types, raised $50 million by offering 2.9 million shares at $17, within the range of $16 to $18. Insiders have indicated an interest in purchasing up to $20 million of the offering. At pricing, the company commands a fully diluted market value of $177 million.
Aziyo Biologics plans to list on the Nasdaq under the symbol AZYO. Piper Sandler and Cowen acted as joint bookrunners on the deal.
Regenerative medicine company Aziyo Biologics prices IPO at $17 midpoint
October 8, 2020

